Cannabinoids may ease withdrawal symptoms, but not stop addiction

Cannabinoid exposure across substance use disorders: Short-term symptom benefits without sustained therapeutic gains in a tier-weighted systematic review.

European psychiatry : the journal of the Association of European Psychiatrists • • Review • Highly Relevant
🤖

AI Summary

This systematic review examined whether cannabinoid exposure helps treat substance use disorders involving opioids, alcohol, cocaine, tobacco, and methamphetamine. Across 97 studies involving 41,954 participants, the review assessed treatment retention, relapse, abstinence, craving, withdrawal severity, and consumption. Overall, the evidence was mixed: beneficial results were reported more often for short-term symptoms than for lasting recovery outcomes.

The review found that 76.4% of beneficial findings involved short-term symptom relief, such as reduced craving or withdrawal severity. However, sustained outcomes—including abstinence, relapse prevention, and treatment retention—were generally not improved, with this pattern most pronounced in opioid use disorder. Because many positive symptom findings came from weaker study designs, the authors conclude that cannabinoids may provide short-horizon relief but have not demonstrated sustained therapeutic benefits. Stronger randomized trials with objectively verified outcomes are needed.

💡 Key Findings

1
Across 97 studies and 41,954 participants, beneficial findings were more common for short-term symptoms than for lasting substance use disorder outcomes.
High
85%
2
Short-term symptom targets accounted for 76.4% of beneficial findings, while positive results for craving, withdrawal severity, and consumption came predominantly from weaker study designs.
High
80%
3
Cannabinoids did not demonstrate sustained benefits for abstinence, relapse prevention, or treatment retention, especially in opioid use disorder.
High
85%
4
The authors call for adequately powered randomized trials using biochemically verified endpoints before cannabinoids can be considered proven long-term adjunctive treatments for addiction.
High
90%

📄 Original Abstract

Cannabinoids are increasingly discussed as adjuncts in addiction treatment, yet whether they improve clinically meaningful substance use disorder (SUD) outcomes beyond short-term symptom relief is unresolved. We determined whether cannabinoid exposure confers directional efficacy across opioid, alcohol, cocaine, tobacco, and methamphetamine use disorders, distinguishing symptomatic targets from sustained therapeutic outcomes. PubMed and Embase (1975-2025) were searched for human studies evaluating cannabinoid exposure in relation to SUD outcomes. Two reviewers independently screened and extracted data. Risk of bias was assessed using RoB 2 for randomized controlled trials (RCTs), ROBINS-I for cohort studies, and JBI checklists for cross-sectional, case, and qualitative designs. Six prespecified endpoints (treatment retention, relapse, abstinence, craving, withdrawal severity, consumption) were mapped to each target SUD. Following Synthesis Without Meta-analysis (SWiM) guidance, structured narrative synthesis used a design-based weighting scheme (RCT 1.00 to qualitative 0.25). PROSPERO: CRD420251151193. Ninety-seven studies (41,954 participants) contributed 195 endpoint instances: 89 Beneficial (45.6%), 80 No Significant Effect (41.0%), 12 Mixed/Partial (6.2%), and 14 Harmful/Inferior (7.2%). Short-term symptom targets accounted for most Beneficial findings (76.4%). Sustained outcomes were predominantly No Significant Effect, most pronounced in opioid use disorder. Beneficial symptom findings derived overwhelmingly from weaker study designs (craving 81.5%; withdrawal severity 85.7%; consumption 80.0%). Cannabinoids confer short-horizon symptomatic benefits but do not demonstrate efficacy for sustained abstinence, relapse prevention, or retention, most clearly in opioid use disorder, where evidence is strongest. Findings for other disorders remain preliminary. Adequately powered adjunctive randomized trials with biochemically verified endpoints are needed.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.